“…However, Guanmutong, Qingmuxiang and Guangfangji have been cancelled (State Food andDrug Administration, 2003, 2004) because the content of aristolochic acids in these three drugs is high enough to cause aristolochic acid nephropathy (AAN). AAN has been reported in some countries, including Belgium (Vanherweghem et al, 1993), England (Lord et al, 1999), Japan (Tanaka et al, 1997), and China (Liu and Zeng, 1994;Ma, 1998 Shang et al, 2000), thin layer chromatography scanning (TLCS; Chen et al, 1994;Cui et al, 2001), high-performance liquid chromatography (HPLC; Liu and Wang, 1990;Hashimoto et al, 1999;Ong et al, 2000;Schaneberg et al, 2002;Kawamura et al, 2003), liquid chromatography-electrospray mass spectrometry (LC/MS; Kite et al, 2002;Chan et al, 2003;Jong et al, 2003;Ioset et al, 2003), and capillary zone electrophoresis (CZE; Ong and Woo, 2001;Li et al, 2004b). However, most of these reports focused on the determination of AA-I or AA-I and AA-II, while no report on the determination of other AAs was found except that the contents of AA-I, AA-II, AA-III, AA-IIIa, AA-IVa, AA-VIIa and AA-E in leaves of Aristolochia debilis were given after HPLC analysis (Nishida and Fukami, 1989).…”